HomeMarket NewsRevolution Medicines: Early-stage Data on Cancer Therapy Causes Stock Plummet

Revolution Medicines: Early-stage Data on Cancer Therapy Causes Stock Plummet

Actionable Trade Ideas

always free

Cancer cells division

Artur Plawgo

Revolution Medicines (NASDAQ:RVMD) experienced a significant drop of approximately 31% in pre-market trading on Monday. The decline followed the release of Phase 1/1b study data for its RASMULTI inhibitor RMC-6236, a cancer therapy targeting non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

The interim data, as of October 12, 2023, revealed an objective response rate of 38% among 40 efficacy-evaluable NSCLC patients who received RMC-6236 once-daily dosing as monotherapy at doses ranging from 80 mg to 400 mg for a minimum of eight weeks.

Among the NSCLC patients, one complete remission and 14 partial remissions (including three unconfirmed PRs) were observed. These patients had previously undergone up to two lines of therapy.

In the case of PDAC patients, 46 efficacy-evaluable individuals saw an objective response rate of 20% after eight weeks of RMC-6236 monotherapy, with nine partial remissions classified as the best responses.

Regarding safety, the most commonly reported treatment-related adverse events (TRAEs) were rash and gastrointestinal-related toxicities. Unfortunately, a severe Grade 4 TRAE resulted in the death of a PDAC patient receiving the 80 mg QD dose.

Moving forward, Revolution Medicines intends to proceed with the dose-optimization portion of the trial. These findings were presented at the ongoing European Society for Medical Oncology (ESMO) Congress meeting in Madrid.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.